5 500 702 500
Royalty revenue from
related-party 16 12 32 25
Total revenue 1,694 928 3,043 1,399
Operating costs and
expenses
Cost of product
revenue 1,199 884 2,212 1,563
Research and
development 1,746 1,661 3,434 3,149
Selling, general and
administrative 3,176 2,203 5,729 4,273
Total operating costs
and expenses 6,121 4,748 11,375 8,985
Loss from operations (4,427) (3,820) (8,332) (7,586)
Interest income 283 298 553 687
Interest expense (25) (132) (50) (396)
Other income 2 - 3 -
Gain on early retirement
of notes payable to
related-party - 1,183 - 1,183
Net loss $(4,167) $(2,471) $(7,826) $(6,112)
Basic and diluted net
loss per share $(0.29) $(0.23) $(0.56) $(0.60)
Shares used in computing
basic and diluted net
loss per share 14,471 10,642 14,037 10,210
Condensed Balance
Sheets (amounts
in thousands) December 31, June 30,
2007 2007
Assets (unaudited) (Note 1)
Cash and investments $30,903 $23,434
Other assets 4,513 3,890
Total assets $35,416 $27,324
Liabilities and
stockholders' equity
Total current
liabilities $3,008 $3,315
Total long-term
liabilities
'/>"/>
SOURCE Cardica, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair2.
Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family3.
Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery4.
Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries5.
Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results6.
Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference7.
Accuray Announces New Treatment Planning Service Offering8.
QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes9.
Sharps Compliance Corp. Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology10.
ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use11.
Vapotherm(R) Announces Validation of U.S. Patent